The Role of Inflammatory Cytokines in Ovarian Cells During the Malignant Transformation of Endometriosis

The Role of Inflammatory Cytokines in Ovarian Cells During the Malignant Transformation of Endometriosis Authors/Creators - 1. Marmara University, Institute of Health Sciences, Department of Biophysics - 2. Marmara University, Nanotechnology and Biomaterials Application and Research Center - 3. Marmara University, Faculty of Medicine, Department of Biophysics - 4. Marmara University, Faculty of Medicine, Department of Medical Microbiology - 5. Marmara University, Faculty of Medicine, Department of Obstetrics and Gynecology Description Endometriosis is a chronic estrogen-dependent inflammatory disease characterized by the presence of ectopic endometrial tissue outside the uterus. Inflammation, angiogenesis, immune regulation, and hormonal signaling pathways play complex roles in its pathogenesis, and these microenvironmental factors are believed to contribute to malignant transformation. Particularly, clinical and molecular data support that endometrioid and clear cell epithelial ovarian cancers (EAOC) can originate from endometriotic lesions. Our central hypothesis is that estrogen and pro-inflammatory cytokines (IL-6, IL-1β, VEGF, EGF, IL-10) within the endometriotic microenvironment facilitate malignant transformation by enhancing proliferation, angiogenesis, and intracellular signaling in ovarian cancer cells. To investigate this, Ishikawa endometrial cells were treated with estrogen and cytokines for 48 hours to create an endometriosis-like microenvironment, which was subsequently applied to OVCAR3 ovarian cancer cells. Cell viability was assessed using the MTT assay, and levels of VEGF (Vascular Endothelial Growth Factor), NGF (Nerve Growth Factor), and PI3K (Phosphatidylinositol 3-Kinase) were quantitatively measured via ELISA. Results showed a significant 2–3 fold increase in cell viability and proliferation in both Ishikawa and OVCAR3 cells following combined treatment with cytokines and estrogen (****p < 0.001). Our model recapitulates key biological processes underlying the malignant transformation of endometriosis. Furthermore, the study contributes to the literature by revealing the influence of microenvironmental factors in the transition from endometriosis to ovarian cancer. In conclusion, this study demonstrates the potential role of an estrogen and cytokine-driven endometriotic microenvironment in malignant transformation, highlighting molecular and cellular targets relevant to EAOC development. These findings suggest that this model could be applied to future studies using primary human cells and provide a foundation for developing translational experimental systems with clinical relevance. Files 2025.2.33-48.pdf Files (421.1 kB) | Name | Size | Download all | |---|---|---| | md5:bfddf6afcf89ff12c73a35531d543049 | 421.1 kB | Preview Download | Additional details Identifiers Related works - Is published in - Journal article: 10.5281/zenodo.17180114 (DOI) Dates - Issued - 2025-09-23 Software - Repository URL - https://www.bbtechjournal.com/doi10-5281-zenodo-17180114/ References - 1. Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020;382(13):1244–1256. doi:10.1056/NEJMra1810764. - 2. Viganò P, Parazzini F, Somigliana E, Vercellini P. Endometriosis: Epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol. 2004;18(2):177–200. doi:10.1016/j.bpobgyn.2004.01.007. - 3. Yoldemir T. Evaluation and management of endometriosis. Climacteric. 2023;26(3):248–255. doi:10.1080/13697137.2023.2190882. - 4. Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D, D'Hooghe T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril. 2009;92(1):68–74. doi:10.1016/j.fertnstert.2008.04.056. - 5. Yoldemir T. MHT in menopausal women at risk: comorbidity endometriosis. Maturitas. 2019;124:119. doi:10.1016/j.maturitas.2019.04.030. - 6. Ozyurek ES, Yoldemir T, Kalkan U. Surgical challenges in the treatment of perimenopausal and postmenopausal endometriosis. Climacteric. 2018;21(4):385–390. doi:10.1080/13697137.2018.1439913. - 7. Kvaskoff M, Mu F, Terry KL, Harris HR, Poole EM, Farland LV, et al. Endometriosis: a high‑risk population for major chronic diseases? Hum Reprod Update. 2015;21(4):500–16. doi:10.1093/humupd/dmv013. - 8. Gibson DA, Simitsidellis I, Collins F, Saunders PTK. Androgens, oestrogens and endometrium: a fine balance between perfection and pathology. J Endocrinol. 2020;246(3):57–73. doi:10.1530/JOE‑20‑0106. - 1. Wang Y, Nicholes K, Shih IM. The origin and pathogenesis of endometriosis. Annu Rev Pathol. 2020;15:71–95. doi:10.1146/annurev‑pathmechdis‑012419‑032655. - 10. Nap AW, Griffioen AW, Dunselman GAJ, Bouma‑Ter Steege JC, Thijssen VL, Evers JLH, Groothuis PG. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab. 2004;89(3):1089–1095. doi:10.1210/jc.89.3.1089. - 11. Machado DE, et al. Higher expression of vascular endothelial growth factor (VEGF) and its receptors in peritoneal fluid and lesions of endometriosis patients. J Exp Clin Cancer Res. 2010;29(4). doi:10.1186/1756‑9966‑29‑4. - 12. Asante A, Taylor C, Horne AW. Endometriosis: the role of neuroangiogenesis. Annu Rev Physiol. 2011;73:163–182. doi:10.1146/annurev‑physiol‑012110‑142103. - 13. Yoldemir T. Postmenopausal endometriosis. Gynecol Endocrinol. 2024;40(1):2441299. doi:10.1080/09513590.2024.2441299. - 14. Linder A, Westbom‑Fremer S, Mateoiu C, et al. Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma. Hum Reprod. 2024; (Advance online publication). doi:10.1093/humrep/deae043. - 15. Gołąbek-Grenda A, Olejnik A. In vitro modeling of endometriosis and endometriotic microenvironment - Challenges and recent advances. Cell Signal. 2022 Sep;97:110375. doi: 10.1016/j.cellsig.2022.110375. Epub 2022 Jun 9. PMID: 35690293. - 16. Kloeckner AA, et al. Endometriosis Cell Spheroids Undergo Mesothelial Clearance in a 3D Model. Cells. 2025;14(10):742. - 17. Lessey BA, Ilesanmi AO, Castelbaum AJ, Yuan L, Somkuti SG, Chwalisz K, Satyaswaroop PG. Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): Progesterone induced expression of the alpha1 integrin. J Steroid Biochem Mol Biol. 1996;59(1):31–39. doi:10.1016/S0960‑0760(96)00103‑3. - 18. Guldorum, Y. Et Al. 2024. Ethosuximide-loaded bismuth ferrite nanoparticles as a potential drug delivery system for the treatment of epilepsy disease. PLoS ONE , vol.19, no.9 . - 19. Tamm Rosenstein K, Simm J, Suhorutshenko M, Salumets A, Metsis M. Changes in the transcriptome of the human endometrial Ishikawa cancer cell line induced by estrogen, progesterone, tamoxifen, and mifepristone (RU486) as detected by RNA sequencing. PLoS ONE. 2013;8(7):e68907. doi:10.1371/journal.pone.0068907. - 20. Zeitvogel A, Baumann R, Starzinski‑Powitz A. Identification of an invasive, N‑cadherin‑expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol. 2001;159:1839–1852. doi:10.1016/S0002‑9440(10)63030. - 21. Banu SK, Lee J, Starzinski‑Powitz A, Arosh JA. Gene expression profiles and functional characterization of human immortalized endometriotic epithelial and stromal cells. Fertil Steril. 2008;90:972–987. doi:10.1016/j.fertnstert.2007.07.1358. - 22. Hirata T, Osuga Y, Takamura M, Kodama A, Hirota Y, Koga K, Yoshino O, Harada M, Takemura Y, Yano T, et al. Recruitment of CCR6-expressing Th17 cells by CCL20 secreted from IL‑1β‑, TNF‑α‑, and IL‑17A‑stimulated endometriotic stromal cells. Endocrinology. 2010;151:5468–5476. doi:10.1210/en.2010‑0398. - 23. Guo P, Bi K, Lu Z, Wang K, Xu Y, Wu H, Cao Y, Jiang H. CCR5/CCR5 ligand‑induced myeloid‑derived suppressor cells are related to the progression of endometriosis. Reprod Biomed Online. 2019;39:704–711. doi:10.1016/j.rbmo.2019.05.014. - 24. Wu Y, Zhu F, Sun W, Shen W, Zhang Q, Chen H. Knockdown of CCL28 inhibits endometriosis stromal cell proliferation and invasion via ERK signaling pathway inactivation. Mol Med Rep. 2022;25(2):56. doi:10.3892/mmr.2021.12573. - 25. Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Oi H. Molecular pathogenesis of endometriosis‑associated clear cell carcinoma of the ovary. Oncol Rep. 2009;22(2):233–240. - 26. Liu J, Wang Y, Chen P, Ma Y, Wang S, Tian Y, Wang A, Wang D. AC002454.1 and CDK6 synergistically promote endometrial cell migration and invasion in endometriosis. Reproduction. 2019;157:535–543. doi:10.1530/REP‑19‑0005. - 27. Barnard ME, Farland LV, Yan B, Wang J, Trabert B, Doherty JA, Meeks HD, Madsen M, Guinto E, Collin LJ, Maurer KA, Page JM, Kiser AC, Varner MW, Allen‑Brady K, Pollack AZ, Peterson KR, Peterson CM, Schliep KC. Endometriosis Typology and Ovarian Cancer Risk. JAMA. 2024;332(6):482–489. doi:10.1001/jama.2024.9210. - 28. Kvaskoff M, Mahamat‑Saleh Y, Farland LV, Shigesi N, Terry KL, Harris HR, Roman H, Becker CM, As‑Sanie S, Zondervan KT, Horne AW, Missmer SA. Endometriosis and cancer: a systematic review and meta‑analysis. Hum Reprod Update. 2021;27(2):393–420. doi:10.1093/humupd/dmaa045. - 29. Steinbuch SC, Lüß AM, Eltrop S, Götte M, Kiesel L. Endometriosis‑Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance. Int J Mol Sci. 2024;25(8):4306. doi:10.3390/ijms25084306. - 30. McLaren J, Prentice A, Charnock‑Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod. 1996;11:220–223. - 31. Liu S, Xin X, Hua T, Shi R, Chi S, Jin Z, et al. Efficacy of Anti‑VEGF/VEGFR agents on animal models of endometriosis: a systematic review and meta‑analysis. PLoS ONE. 2016;11:e0166658. doi:10.1371/journal.pone.0166658. - 32. Li WN, Hsiao KY, Wang CA, Chang N, Hsu PL, Sun CH, Wu SR, Wu MH, Tsai SJ. Extracellular vesicle‑associated VEGF‑C promotes lymphangiogenesis and immune cells infiltration in endometriosis. Proc Natl Acad Sci U S A. 2020;117(41):25859–25868. doi:10.1073/pnas.1920037117. - 33. Liu D, Liu M, Yu P, Li H. Brain‑derived neurotrophic factor and nerve growth factor expression in endometriosis: A systematic review and meta‑analysis. Taiwan J Obstet Gynecol. 2023;62(5):634–639. doi:10.1016/j.tjog.2023.07.003. - 34. Sreya M, Tucker DR, Yi J, Alotaibi FT, Lee AF, Noga H, Yong PJ. Nerve Bundle Density and Expression of NGF and IL‑1β Are Intra‑Individually Heterogenous in Subtypes of Endometriosis. Biomolecules. 2024;14(5):583. doi:10.3390/biom14050583. - 35. Driva TS, Schatz C, Haybaeck J. Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis. Biomolecules. 2023 Aug 16;13(8):1253. doi: 10.3390/biom13081253. PMID: 37627318; PMCID: PMC10452661. - 36. Nakamura A, Tanaka Y, Amano T, Takebayashi A, Takahashi A, Hanada T, Tsuji S, Murakami T. mTOR inhibitors as potential therapeutics for endometriosis: a narrative review. Mol Hum Reprod. 2024 Dec 11;30(12):gaae041. doi: 10.1093/molehr/gaae041. PMID: 39579091; PMCID: PMC11634386.